Mrs. Danielle Loreno Dalfrey, MSN, APRN, FNP-BC Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 14513 Waterloo Dr, Ventress, LA 70783 Phone: 318-518-6865 |
News Archive
Twice-yearly intravenous infusion with denosumab, a new targeted therapy to stop bone loss, increased bone density and prevented spinal fractures in men receiving androgen-deprivation therapy for prostate cancer. The report from an international research study, the first to document reduced fracture risk in men receiving the hormone-blocking treatment, was published today in the print edition of the New England Journal of Medicine (NEJM). Both fundamental research on rank ligand (RANKL) in prostate cancer bone metastasis and other molecular factors involved in the denosumab study were supported at Massachusetts General Hospital with funding from the Prostate Cancer Foundation (PCF).
For most men with low-risk prostate cancer, the recommended strategy is active surveillance with regular testing to check for cancer growth rather than immediate treatment, according to guidelines from the American Society of Clinical Oncology.
The combination of the immunotherapy drug ipilimumab and the investigational antibody drug nivolumab led to long-lasting tumor shrinkage in more than half of patients with metastatic melanoma, according to results from a Phase I trial simultaneously published online on Sunday, June 2, in The New England Journal of Medicine and presented by Memorial Sloan-Kettering Cancer Center researchers at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO).
Africa's economies are expanding, but the continent is still too dependent on the export of raw materials and trade between African nations needs to be increased, the African Progress Panel said in a report released Thursday at the World Economic Forum on Africa, which is taking place this week in Cape Town, the Associated Press/Washington Post reports.
OncoSec Medical Incorporated, which is developing its advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumor cancers, announced today that it has entered into definitive agreements with institutional investors to purchase $7.75 million of securities in a registered public offering.
› Verified 9 days ago